NCT00515424View on ClinicalTrials.gov

Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

PHASE1CompletedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

July 31, 2007

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

RKI983

Trial Locations (5)

Unknown

Artesia

Rochester

Charlotte

Durham

Houston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY